araag2/HINT huggingface dataset:
Clinical trial NCT02628028 (phase 2, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ly3337641, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the trial was terminated after an interim analysis of efficacy and safety data did not warrant
    continuation of the trial.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female subjects of childbearing potential test negative for pregnancy at screening and
             agree not to breastfeed

          -  Female subjects: agree to use a reliable method of birth control from the start of
             screening until 28 days after the last dose of study drug or be of nonchildbearing
             potential

          -  Male subjects: agree to use a reliable method of birth control from the start of
             screening until 2 weeks after the last dose of study drug or have undergone vasectomy

          -  Have a diagnosis of RA based on the 2010 American College of Rheumatology
             (ACR)/European League against Rheumatism criteria

          -  Have at least 1 of the following:

               -  rheumatoid factor or anti-citrullinated peptide antibodies (ACPA) at screening OR

               -  radiographs documenting bony erosions

          -  Have active RA, defined as:

               -  Part A: ≥3 swollen joints (based on 66-joint counts)

               -  Part B:

               -  ≥6 swollen joints (based on 66-joint counts)

               -  ≥6 tender joints (based on 68-joint counts)

               -  hsCRP levels greater than the upper limit of normal (ULN) OR positive for ACPA

          -  Part B only: Have had inadequate response, loss of response, or intolerance to at
             least 1 synthetic OR biologic disease-modifying antirheumatic drug (DMARD)

        Exclusion Criteria:

          -  Have received any of the following:

               -  Part B only: any prior treatment with a product directly targeting Bruton's
                  tyrosine kinase (BTK) (marketed or investigational)

               -  belimumab, natalizumab, or vedolizumab within 6 months prior to baseline

               -  B-cell-depleting agents (such as rituximab) or other cell-depleting biologics
                  (eg, anti-cluster of differentiation 3 (CD3) antibody) within 12 months prior to
                  screening for Part A or at any time prior to screening for Part B

          -  Have known hypogammaglobulinemia

          -  Have hepatitis C virus, hepatitis B virus or human immunodeficiency virus

          -  Have active tuberculosis (TB)

          -  Are at high risk of infection or have recent evidence of clinically significant
             infection

          -  Have had lymphoma, leukemia, or any malignancy within the previous 5 years except for
             treated basal cell or squamous epithelial carcinomas of the skin

          -  Have received a live (attenuated) vaccine within 28 days prior to baseline or plan to
             receive one during the study
Clinical trial NCT02629822 (phase 2, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: doravirine, tenofovir, lamivudine
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is HIV-1 positive within 45 days prior to the treatment phase of this study, and have
             HIV treatment indicated based on physician assessment.

          -  Is naïve to antiretroviral therapy (ART) including investigational antiretroviral
             agents.

          -  Prior to screening, have had a genotype performed confirming the presence of only one
             of the following NNRTI mutations: K103N, Y181C, or G190A.

          -  Is considered clinically stable with no signs or symptoms of active infection at time
             of entry into the study (i.e. clinical status and all chronic medications should be
             unchanged for at least 2 weeks prior to the start of treatment in this study).

          -  Is highly unlikely to become pregnant or to impregnate a partner

        Exclusion Criteria:

          -  Is a user of recreational or illicit drugs or has had a recent history of drug or
             alcohol abuse or dependence.

          -  Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an
             agent that is active against HIV-1, including, but not limited to, adefovir,
             tenofovir, entecavir, emtricitabine, or lamivudine.

          -  Has documented or known resistance to study drugs (doravirine, lamivudine, and/or
             tenofovir)

          -  Has participated or anticipates participating in a study with an investigational
             compound/device within 30 days prior to signing informed consent

          -  Has any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other
             immunosuppressant drugs during the course of the trial.

          -  Requires or anticipates requiring any of the prohibited medications

          -  Has significant hypersensitivity or other contraindication to any of the components of
             the study drug

          -  Has a current (active) diagnosis of acute hepatitis due to any cause

          -  Has evidence of decompensated liver disease or has liver cirrhosis and a Child-Pugh
             Class C score or Pugh-Turcotte (CPT) score > 9

          -  Is pregnant, breastfeeding, or expecting to conceive

          -  Is female and expecting to donate eggs, or is male and is expecting to donate sperm at
             any time during the study
Clinical trial NCT02632786 (phase 2, status: completed)
Conditions: al amyloidosis
ICD codes: E85.81
Drugs: neod001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age ≥18 years

          2. Confirmed diagnosis of systemic AL amyloidosis

          3. ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic
             response

          4. Cardiac involvement

          5. NT-proBNP ≥650

        Exclusion Criteria:

          1. Non-AL amyloidosis

          2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma

          3. NT-proBNP >5000

          4. Received Plasma cell directed chemotherapy within 6 months

          5. Received autologous stem cell transplant (ASCT) within 12 months
Clinical trial NCT02633800 (phase 2, status: terminated)
Conditions: head and neck neoplasms
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: patritumab, cetuximab, cisplatin, carboplatin, placebo
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    trial was terminated by sponsor due to lack of efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Has histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from
             its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx,
             and larynx

          -  Has or be willing to provide tumor tissue for testing

          -  Has measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST)
             version 1.1

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Has adequate hematological function per protocol

          -  Has adequate renal function per protocol

          -  Has adequate hepatic function per protocol

          -  Agrees to use effective contraception while on the study and for 6-months after the
             end of the study

          -  Provides written informed consent(s)

        Exclusion Criteria:

          -  Has left ventricular ejection fraction (LVEF) <50%

          -  Had prior epidermal growth factor receptor (EGFR) targeted regimen

          -  Had prior anti-human epidermal growth factor receptor 3 (anti-HER3) therapy

          -  Had prior chemotherapy for recurrent/metastatic disease

          -  Had anti-cancer therapy between biopsy and submission of sample

          -  Has history of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ disease, or other solid tumors curatively treated with no
             evidence of disease for ≥ 2 years

          -  Has known history of brain metastases or active brain metastases

          -  Has uncontrolled hypertension

          -  Has clinically significant electrocardiograph (ECG) findings

          -  Had myocardial infarction within 1 year before enrollment, symptomatic congestive
             heart failure, unstable angina, or arrhythmia requiring medication

          -  Had platinum-containing drug therapy with radiotherapy less than 6 months before study
             drug treatment

          -  Had therapeutic or palliative radiation therapy or major surgery within 4 weeks before
             study drug treatment
Clinical trial NCT02637323 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: fx006 32 mg, tca ir 40
SMILES: OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Written consent to participate in the study

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Symptoms associated with OA of the knee for ≥ 6 months prior to Screening (patient
             reported is acceptable)

          -  Currently meets American College of Rheumatology (ACR) Criteria (clinical and
             radiological) for OA

          -  Index knee pain for >15 days over the last month (as reported by the patient)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Ambulatory and in good general health

        Exclusion Criteria:

          -  Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, or arthritis associated with inflammatory bowel disease

          -  History of infection in the index knee joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee within 1 month of Screening

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint within 12 months of Screening

          -  IA corticosteroid (investigational or marketed) in any joint within 6 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Intravenous or Intramuscular corticosteroids (investigational or marketed) within 3
             months of Screening

          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening

          -  Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2
             weeks of Screening

          -  Any other IA investigational drug/biologic use within 6 months of Screening or 5
             half-lives (whichever is longer)

          -  Prior use of FX006

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
Clinical trial NCT02637557 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: iw-3718, matching placebo, ppi
SMILES: CC1=CC(O)=CC(C)=C1Cl, COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is an ambulatory, community-dwelling male or nonpregnant female and is at
             least 18 years old at the Screening Visit. Lactating females must agree not to
             breastfeed.

          -  Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or
             regurgitation) on ≥ 4 days per week during the 8 weeks before the Screening Visit
             while taking standard QD PPI therapy.

        Exclusion Criteria:

          -  Patient may not meet any of the excluded conditions specified in the protocol

          -  Patient has any alarm symptoms including but not limited to GI bleeding, anemia,
             vomiting, dysphagia, or unexpected weight loss any time during the Screening or
             Pretreatment Periods

          -  Patient has a history of clinically significant hypersensitivity or allergies to any
             of the excipients contained in the study medication (active or placebo).

        NOTE: Additional inclusion/exclusion criteria may apply.
Clinical trial NCT02637960 (phase 2/phase 3, status: completed)
Conditions: nocturia
ICD codes: R35.1
Drugs: fedovapagon 2 mg, placebo
SMILES: CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C=C1C)C(=O)N1CCCCC2=C1C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult males ≥18 years [no upper limit]

          -  Benign prostatic hyperplasia

          -  Persistent nocturia despite previous lifestyle modification advice including
             appropriate fluid management

          -  Serum sodium not below lower limit of normal prior to randomization

          -  Provide signed and dated informed consent before any study-specific procedures are
             conducted.

          -  Able to comply with the requirements of the study.

        Exclusion Criteria:

        -
Clinical trial NCT02639533 (phase 2/phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Fulfill ACR 2010 criteria for fibromyalgia diagnosis.

          -  Literate.

          -  Mean VAS for pain higher than 6 in the last 3 months.

        Exclusion Criteria:

          -  Pregnancy or inadequate use of validated contraceptive method.

          -  Contraindications for Transcranial Magnetic Stimulation.

          -  Alcohol of drugs abuse in the last 6 months.

          -  Any severe neurological, neurosurgical, cardiac, endocrinological, or oncological
             disease (current or past).

          -  Decompensated chronic systemic disease.

          -  Previous use of Pregabalin.
Clinical trial NCT02640573 (phase 2, status: terminated)
Conditions: hemoglobin sc disease
ICD codes: D56.5, D56.4, D58.2, D59.5, D59.6, R82.3
Drugs: hydroxyurea
SMILES: NC(=O)NO
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of HbSC disease

          -  Score of 80 or lower on the AdultQLTM 3.0 Sickle Cell Disease Module, or any disease
             related complication, including, but not limited to, one or more pain events per year,
             proliferative sickle retinopathy, avascular necrosis, cholelithiasis, or any
             thrombotic event. If the subject has a score >80, they may still enroll on the trial,
             and be analyzed for secondary endpoints. They will be excluded from analysis of the
             primary endpoint.

        Exclusion Criteria:

          -  Failure to meet inclusion criteria

          -  Hydroxyurea usage in the last 3 months.

          -  Chronic RBC transfusion therapy

          -  Packed red blood cell transfusion in the last 3 months (temporary exclusion).

          -  Pregnancy, or refusal to use medically effective birth control if female and sexually
             active.

          -  Current phlebotomy therapy
Clinical trial NCT02644057 (phase 2, status: withdrawn)
Conditions: cardiorenal syndrome
ICD codes: Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: milrinone, dobutamine
SMILES: CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1, NC[C@H](O)C1=CC(O)=C(O)C=C1
Reason stopped: 
    could not enroll patients
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age >18 years

          2. Admitted to the hospital with a primary diagnosis of Decompensated Heart Failure

          3. Onset of cardio-renal syndrome (increasing creatinine>0.3mg/dl) after or before
             hospitalization. After hospitalization within 7 days of from the time of admission
             after receiving intravenous diuretics and heart failure medication optimization.
             Before hospitalization in the setting of escalating doses of outpatient loop diuretics
             and heart failure medication optimization

          4. Persistent volume overload- For patients with a pulmonary artery catheter, peristent
             volume overload will include :

             Pulmonary capillary wedge pressure >22mm Hg and one of the following clinical signs
             :2+ peripheral edema and/or pulmonary edema or pleural effusion on chest Xray. For
             patients without a pulmonary artery catheter- persistent volume overload will include
             atleast 2 of the following: 2+ peripheral edema , jugular venous pressure >10 mm Hg
             and pulmonary edema or pleural effusion on chest Xray

          5. BNP>400

          6. Cr-1.2-3.0

        Exclusion Criteria:

          1. Intravascular volume depletion

          2. Acute coronary syndrome within 4 weeks

          3. Indication for hemodialysis

          4. Systolic Blood pressure <90mm Hg or MAP<60mm Hg at the time of enrollment

          5. Alternate explanation for worsening renal function , such as obstructive nephropathy ,
             contrast induced nephropathy , ATN

          6. Clinical instability likely to require the addition of intravenous vasoactive drugs
             including vasodilators and/or inotropic drugs

          7. The use of iodinated radio-contrast material in the past 72 hours or anticipated use
             of intravenous contrast during the current hospitalization

          8. Underlying rhythm disorder
Clinical trial NCT02651714 (phase 2, status: completed)
Conditions: atopic dermatitis, eczema, chronic pruritus
ICD codes: L20.89, L20.9, B00.0, L20.82, L20.84, L20.83, H01.131, H01.132, H01.133
Drugs: tradipitant, placebo
SMILES: FC(F)(F)C1=CC(=CC(CN2N=NC(=C2C2=CC=NC=C2)C2=NC=CC=C2C(=O)C2=CC=CC=C2Cl)=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and non-pregnant, non-lactating female subjects aged 18 - 65 years (inclusive);

          -  Diagnosed with atopic dermatitis

          -  Suffering from chronic pruritus with pruritus being actively present

        Exclusion Criteria:

          -  Chronic pruritus due to condition other than atopic dermatitis (AD)

          -  Participation in a previous tradipitant (LY686017 or VLY-686) trial;

          -  Anyone affiliated with the site or sponsor and/or anyone who may consent under duress;

          -  Any other sound medical reason as determined by the Investigator including any
             condition which may lead to an unfavorable risk-benefit of study participation, may
             interfere with study compliance or may confound study results.
Clinical trial NCT02653599 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ttp273, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and
             meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus.

          -  On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for
             the last 3 months prior to screening.

          -  Males. Females of non-childbearing potential.

          -  Generally stable health without a history of major surgery or significant injuries
             within the last year and without an active infection.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young,
             insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus,
             or history of diabetic ketoacidosis.

          -  Participation in a clinical trial and receipt of an investigational product within 30
             days.

          -  Participation in any formal weight loss program, or fluctuation of > 5% in body
             weight, or having received medications approved for weight loss within 3 months prior
             to screening or contemplating such therapy during the trial.

          -  Previous surgical treatment of obesity.

          -  Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice
             administered by someone other than the patient within 6 months prior to screening.

          -  Use of other diabetic agents except metformin within 3 months prior to Screening.

          -  History of pancreatitis.

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening.

          -  History of hemolytic anemia, chronic transfusion requirement or other condition
             rendering HbA1c results unreliable.

          -  History of MEN-2 or family history of medullary thyroid cancer.

          -  History or presence of clinically significant disease (other than Type 2 diabetes
             mellitus).
Clinical trial NCT02654132 (phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: elotuzumab, pomalidomide, dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of
             lenalidomide and a proteosome inhibitor alone or in combination

          -  Documented refractory or relapsed and refractory multiple myeloma

          -  Refractory to proteosome inhibitor and lenalidomide, and to last treatment

          -  Relapsed and refractory patients must have achieved at least a partial response to
             previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed
             within 6 months, and were refractory to their last treatment

          -  Measurable disease at screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria:

          -  Active plasma cell leukemia

          -  Prior treatment with pomalidomide

          -  Unable to tolerate thromboembolic prophylaxis while on the study

          -  Prior autologous stem cell transplant within 12 weeks

          -  Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Clinical trial NCT02654483 (phase 2, status: completed)
Conditions: epidermolysis bullosa, pruritus
ICD codes: Q81.0, Q81.1, Q81.2, Q81.8, Q81.9, L12.30, L12.35, L29.0, L29.1, L29.2, L29.8, L29.9, L29.3
Drugs: vpd-737
SMILES: C[C@@H](O[C@H]1CC[C@@H]2CN(C[C@H]2[C@@H]1C1=CC=C(F)C=C1)C1=CC(=O)CC1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus

        Exclusion Criteria:

          -  Chronic liver or renal disease